Title: p73 is required for vessel integrity controlling endothelial junctional dynamics through Angiomotin

Laura Maeso-Alonso[1], Hugo Alonso-Olivares[1], Nicole Martínez-García[2], Javier Villoch-Fernández[1], Lorena Lopez-Ferreras[1], Laura Puente-Santamaría[3], Natalia Colas-Algora[4], Alfonso Fernández-Corona[5], María Elena Lorenzo-Marcos[5], Benilde Jiménez[3,6], Lars Holmgren[7], Margareta Wilhelm[8], Jaime Millan[4], Luis del Peso[3,6], Lena Claesson-Welsh[9], Margarita M. Marques[10], Maria C. Marin[1]*

[1]Instituto de Biomedicina y Departamento de Biología Molecular, Universidad de León (Spain)

[2]Instituto de Biomedicina y Departamento de Producción Animal, Universidad de León (Spain)

[3]Departamento de Bioquímica, Universidad Autónoma de Madrid (UAM), Instituto de Investigaciones Biomédicas "Alberto Sols" CSIC-UAM, Madrid (Spain)

[4]Centro de Biología Molecular "Severo Ochoa" (CSIC-UAM), Madrid (Spain).

[5]Complejo Asistencial Universitario de León, León (Spain)

[6]IdiPaz, Instituto de Investigación Sanitaria del Hospital Universitario La Paz, Madrid (Spain)

[7]Department of Oncology-Pathology, Bioclinicum, Karolinska Institutet, Stockholm 17164 (Sweden)

[8]Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, 171 65 Stockholm (Sweden)

[9]Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Science for Life Laboratory Uppsala University, Uppsala (Sweden).

[10]Instituto de Desarrollo Ganadero y Sanidad Animal y Departamento de Producción Animal, Universidad de León (Spain)

***Corresponding author: mmarv@unileon.es; ORCID: 0000-0002-7149-287X; Departamento de Biología Molecular, Universidad de León, Campus de Vegazana sn, 24071 León (Spain).

Abstract

Preservation of blood vessels integrity, which is critical for normal physiology and organ function, is controlled at multiple levels, including endothelial junctions. However, the mechanism that controls the adequate establishment of endothelial cell junctions is not fully defined. Here we uncover TAp73 as a vascular architect that orchestrates transcriptional programs involved in cell junction establishment and developmental blood vessel morphogenesis and identify Angiomotin (AMOT) as a TAp73 direct transcriptional target. Knockdown of p73 in endothelial cells not only results in decreased Angiomotin expression and localization at intercellular junctions, but also affects its downstream function regarding Yes-Associated Protein (YAP) cytoplasmic sequestration upon cell-cell contact. Analysis of adherens junctional morphology after p73-knockdown revealed striking alterations, particularly a sharp increase in serrated junctions and actin bundles appearing as stress fibers, both features associated with enhanced barrier permeability. In turn, stabilization of Angiomotin levels rescued those junctional defects, confirming that TAp73 controls endothelial junction dynamics, at least in part, through the regulation of Angiomotin. The observed defects in monolayer integrity were linked to hyperpermeability and reduced transendothelial electric resistance. Moreover, p73-knockout retinas showed a defective sprout morphology coupled to hemorrhages, highlighting the physiological relevance of p73 regulation in the maintenance of vessel integrity *in vivo*. We propose a new model in which TAp73 acts as a vascular architect integrating transcriptional programs that will impinge with Angiomotin/YAP signaling to maintain junctional dynamics and integrity, whilst balancing endothelial cell rearrangements in angiogenic vessels.

Keywords: p73, Angiomotin (AMOT), cell junctions, endothelial barrier integrity, YAP, vascular morphogenesis and angiogenesis

Introduction

Formation of blood vessel networks by sprouting angiogenesis is critical for tissue growth, homeostasis and regeneration. During this process, the rearrangements of tip- and stalk-cells require dynamic remodeling of cell-cell junctions while maintaining the integrity of the new sprout to ensure proper barrier functionality [1]. In this context, endothelial cells (EC) junctions play a coordinating role, polarizing the activity of the migration machinery and maintaining the sprout cohesion [2]. Loss of these junctions promotes hemorrhages and edemas and also plays an important role during tumor angiogenesis [3]. Junction-associated proteins, like the angiomotin family member Angiomotin (AMOT) are involved in the regulation and coordination of front–rear polarity and contribute to the assembly of EC junctions and the stabilization and maturation of vessels [4-7]; however, the identification of upstream regulators of these proteins remain elusive.

In this regard, the *TP73* gene has been described as an essential player during angiogenesis [8-10]. *TP73* can give rise to different functional isoforms: TAp73 with full transactivation activity, and the truncated dominant-negative DNp73 [11]. DNp73 functions as a pro-angiogenic signaling factor in tumor cells [9, 10, 12], whereas a bi-functional role in tumor angiogenesis has been proposed for TAp73 [8, 10, 13]. However, the mechanism of TAp73 physiological function during developmental vascular morphogenesis has not been unraveled. The *Trp73-/-* mice (p73KO), which lack both isoforms, exhibit extensive gastrointestinal and cranial hemorrhages [14], suggestive of vascular fragility and/or other defects in their vascular compartment. p73 deficiency also leads to perturbed vascular development in the mouse retina, with a decrease in vascular branching and elongation, and anastomosis defects [9]. Interestingly, similar defects have previously been associated with altered stability or dynamics of EC junctions [15-19]. However, whether TAp73-deficiency in EC leads to junctional defects with important consequences for vascular morphogenesis, remains an important open question.

In this work we demonstrate p73 essential role in the maintenance of the endothelial junction dynamics and barrier integrity. Our results demonstrate that p73 regulates endothelial junction dynamics, at least in part, via AMOT, linking for the first time p73 and the AMOT/YAP pathway in the regulation of endothelial junctions. Thus, it situates p73 function in the hub of upstream regulators that control how endothelial cells establish and maintain adequate junctions to shape functional vascular networks with important consequences in the maintenance of vascular homeostasis.

Material and methods

Mice husbandry, animal breeding and genotyping

Trp73$^{-/-}$ mice (p73KO) and DNp73 mutant mice (DNp73KO) were obtained as described before [20]. Male and female littermates were used for the experiments and genotyping was performed according to [14, 20].

Retina dissection and flat-mount preparation

Retinal extraction and flat-mount preparation were performed as described in [9]. Eyes from postnatal mice on day 7 (P7) were extracted from either perfused or non-perfused mice. In the latter case, eyes were fixed with 4% PFA during 40 min and stained immediately. Wholemount (WM) staining was performed according to [9], using VE-cadherin (BD #555298, Clone 11D4.1, 1:100 dilution, retinas from perfused mice) or TER119 (R&Dsystems #MAB1125-SP, 1:100 dilution, retinas from non-perfused mice) primary antibodies, and a donkey anti-Rat Alexa Fluor 488 (Invitrogen, # A21208) as secondary antibody, as well as biotin-conjugated isolectin B4 (IB4, Sigma-Aldrich, #L2140).

Cell culture

Generation and culture of murine wild type (WT) and p73KO-induced pluripotent stem cells (iPSCs) has been described elsewhere [21]. iPSCs were cultured on MEFs feeder cells (5 × 104 cells/cm^2) in Dulbecco´s Modified Eagle Medium (DMEM, Sigma-Aldrich, #D5671) supplemented with 15% FBS, 2 mM L-glutamine, 1 mM sodium pyruvate, 1 mM nonessential amino acids, 0.1 mM β-mercaptoethanol and 1000 U/ml Leukemia Inhibitory Factor (LIF, Millipore, #ESG1107).

Wild type E14TG2α mouse embryonic stem cells (E14-WT, mESCs) were kindly provided by Dr. Jim McWhir (former researcher at Roslin Institute, Edinburgh, Scotland, UK). TAp73-deficient cells (E14-TAp73KO) were generated by gene editing and cultured as previously described [22].

Human Umbilical Vein Endothelial Cells (HUVEC) were isolated from the veins of umbilical cords following the established protocol [23]. Cells were routinely maintained on 0.1% gelatine-coated flasks in endothelial basal medium, with full supplements (EBM Lonza, #CC3124). Cells were used for experiments between passage 4 to 8.

The human cell line HA-TAp73β-Saos2-Tet-On [24], was kindly provided by Dr. Karen Vousden (Cancer Research UK Beatson Institute, Glasgow), and cultured as described in [25]. For TAp73 induction, cells were treated with 2.5 µg/ml of doxycycline (DOXO) for 36 h.

Three-dimensional (3D) endothelial differentiation

Endothelial differentiation assays were carried out as previously reported [9, 26]. Briefly, embryoid bodies (EBs) were formed by the hanging drop method and embedded in a collagen I matrix composed of Ham's F12 medium (Sigma-Aldrich, #D8900), 6.26 mM NaOH, 12.5 mM HEPES, 0.073% NaHCO3, 1% GlutaMAX™ and 1.5 mg/ml collagen I (Advanced Biomatrix, #5005), supplemented with 100 ng/ml VEGF-A (Peprotech, #450-32). Sprouts were analysed after 12 days of *in vitro* culture (iPSCs) or at day 21 (mESCs).

HUVEC Knockdown studies

Two different approaches were conducted to knockdown p73 expression. For synthetic small interfering RNA (siRNA), 5 × 10^5 cells were nucleofected (Amaxa® HUVEC Nucleofector® Program A-034, Kit #VAPB-1002, Lonza) with 50 nM of the following siRNA oligos: scrambled (5´UAGCCACCACUGACGACCUdTdT3´, 5´dTdTAUCGGUGGUGACUGCUGGA3´), or sip73 (i4: 5´CCAUCCUGUACAACUUCAUGUG3´, 5´CAUGAAGUUGUACAGGAUGGUG3´) [27]. After nucleofection, cells were immediately seeded on 0.1% gelatine-coated 6-well plates and analysed after 48-96 h. Lentiviral vector-based RNA interference was carried out with a combination of two lentiviral vectors encoding short hairpin RNA to enhance the silencing efficiency: LV pGIPZ shp73ex5 (clone id V2LHS_69894) and LV pGIPZ shp73ex9 (clone id V3LHA_330455). An empty pGIPZ vector (Dharmacon, # RHS4349) was used as control (VECTOR). Lentiviruses at a multiplicity of infection (MOI) of 20 (10 MOI of each plasmid in case of shp73) were added to the culture medium (plus 8 µg/ml polybrene) for 8 h, resulting in more than 95% transduced cells (pGIPZ includes a GFP reporter). Seventy-two hours later, cells were seeded either at 7,5 × 10^4 cells/cm^2 (high density) or 1 × 10^4 cells/cm^2 (low density conditions) on 0.1% gelatine-coated plates and were analysed after 72 or 96 h.

For AMOT stabilization experiments, transduced cells were seeded at 7,5 × 10^4 cells/cm^2 and after 48-72 h, cells were treated with the tankyrase inhibitor XAV939 (5µM, Sigma-Aldrich, #CX3004) for 24 h.

HUVEC Endothelial barrier function assays

The *in vitro* vascular permeability assay (Millipore, # ECM644-24 wells) was performed following the manufacturer's instructions. Trans-endothelial electric resistance (TEER) assays with an electric cell-substrate impedance sensing system (ECIS 1600R; Applied Biophysics) [28] were performed as described [29]. Briefly, 150,000 infected cells were plated onto 8W10E PET arrays (ibidi #72001) and multifrequency measurement was carried out (ranges between 250 and 64000 Hz) for 24 h.

Immunofluorescence and confocal microscopy image acquisition

Cells were fixed with 3.7% PFA (or 3.7% PFA + 0.5% Tx-100 in the case of ZO-1 staining) during 15 min at RT. After washing (1X PBS), cells were incubated for 15 min in permeabilization buffer (0.5% Tx100 in 1X PBS), blocked for 1 h (10% goat serum in PBS) and incubated with the corresponding primary antibodies at 4 ºC overnight (o/n) (Table 1). Then, cells were washed (1X PBS) and incubated for 45 min at RT with the secondary antibodies (Table 1). Finally, they were stained with DAPI (1 µg/ml), Phalloidin-TRICT (Sigma Aldrich P1951; 1:100 dilution) or Phalloidin-488 (Thermo Fisher Scientific A12379, 1:100) as indicated, and mounted with Fluoromount-G™ (Electron Microscopy Sciences #17984-25). The immunostaining of 3D-endothelial differentiated cells was performed following the protocol of (Fernandez-Alonso et al., 2015). Confocal microscopy images (8bits) were obtained in a Zeiss LSM800 Confocal Laser Scanning Microscope using 25x Plan-Apo/0.8 numerical aperture or 63x Plan-Apo/1.4 numerical aperture oil objectives at RT. In some cases, a 0.5 zoom was used. Confocal Z-stack images were acquired in all cases and stacks were z-projected to maximum intensity. Images were processed with the ZEN blue software (Carl Zeiss Microscopy GmbH).

Image analysis and quantification

For image quantification, semi-automatic macros designed with Image J/Fiji software [30] were applied to confocal Z-stack pictures. AMOT fluorescence intensity at cell periphery was quantified by drawing a Region of Interest (ROI) around cell periphery using VE-Cadherin channel (Total) and another ROI delimiting VE-Cadherin intracellularly (Cytoplasm). "XOR" option was used to subtract the cytoplasm selection from the Total region and to obtain the Periphery region. Amot Mean Fluorescence Intensity (MFI) was measured using AMOT channel. For YAP ratio quantification a Gaussian Blur filter ($\sigma = 2$) was applied to the DAPI channel and images were binarized using an automatic threshold. The "Analyse particles" plug-in was used to identify the number of cells in the image. Then, the cell region was drawn manually (ROI). "XOR" option was used to subtract the nuclei selection from the cell region and obtain the cytoplasmic region. The mean intensity of YAP at nuclei and cytoplasmic region was measured. Proliferation analysis was performed using "Analysed particles" option for DAPI and KI67 channels.

For *in vivo* permeability quantification, blood vessels were selected using the IB4-channel which was binarized with an automatic threshold. Blood vessel selection was overlapped with TER119 staining and "clear" or "clear out" options were used for outside or inside particle quantification, respectively. "Analyse particles" option was used to count TER119-stained particles for each condition and particle percentage was calculated for each image.

RNA Sequencing (RNA-seq) and Transcriptome Data Analysis

Whole transcriptome sequencing from two biological replicates per condition was carried out at the Genomics and Proteomics Service of the National Centre for Oncological Research (CNIO, Madrid). RNA-seq was conducted on the HiSeq Illumina and 20 million reads were generated for each library. Sequencing reads were aligned to the transcriptome with TopHat (v 2.1.1; http://ccb.jhu.edu/software/tophat/index.shtml) provided with known gene annotations and other transcript data (GTF file) taken from the Ensembl (release 84) gene set for the

GRCm38/mm10 mouse genome assembly. Alignment data were quantitated with HTSeq [31]. Differential gene expression analysis was subsequently performed with DESeq2 [32]. Genes were assigned as differential expressed genes (DEGs) if they had an adjusted p-value < 0.05.

Gene ontology (GO) and Functional Annotation Clustering were performed using DAVID Bioinformatics Resources 6.834 [33, 34], choosing level 3 of GO terms specificity. Clustering results were plotted using the ggplot2 library from R (3.5.1) Core Team (2014). Genes shared by the selected clusters were identified, and the results were plotted with Cytoscape 3.7.2 [35]. Venn diagrams were created using BioVenn (http://www.biovenn.nl/) [36].

RNA isolation, reverse transcription, and quantitative real-time PCR (qRT-PCR)

Total RNA isolation and cDNA synthesis were performed using the RNeasy Mini Kit (Qiagen, #74106) and the High-Capacity RNA-to-cDNA™ Kit (Applied Biosystems, #4387406), respectively. Gene expression levels were detected by qRT-PCR in a StepOnePlus™ Real-Time PCR System (Applied Biosystems) using FastStart Universal SYBR Green Master mix (Roche, #4913850001). All protocols were performed according to the manufacturer's instructions. Primers sequences are listed in Table 2.

Chromatin immunoprecipitation assay (ChIP)

In silico prediction of the p73 responding element (RE) within the human *AMOT* gene (ENSG00000126016-; Transcript ID ENST 00000371959.7) was performed using the open access database for eukaryotic transcription factor binding profiles JASPAR [37]. Matrix models MA0861.1 and MA0525.1 were applied, and a site with a score of 13.3 was selected for further *in vitro* analysis. Primers encompassing the p73RE in human AMOT gene were as follows: F →5'-TGTCCCCTTTTCTGCAGAGC -3´ and R→5'- GCTCCCCACTGACACGTTAA -3´.

ChIP analysis was carried out in HA-TAp73β-Saos2-Tet-On cells as described [25], using the following antibodies: anti-HA (Y-11) (Santa Cruz Biotechnology, #sc805), anti-p73 (EP436Y) (Abcam, # ab40658) and anti-p53 (C-19) (Santa Cruz Biotechnology, #sc1311).

Western blot analysis

Protein isolation and electrophoresis were performed as previously published [22]. Nitrocellulose membranes were incubated with rabbit anti- AMOT 1:600 (provided by Dr. Lars Holmgren, Karolinska Institutet, Stockholm, Sweden) or mouse anti-GADPH 1:1500 (Abcam, #ab8245), diluted in 2.5% non-fat dried milk/TBS-T (Tris Buffer Saline-0.05% Tween 20), at 4 ºC o/n with gentle agitation. After washing with TBS-T, membranes were incubated with 25 ng/ml horseradish peroxidase-coupled secondary antibody (Pierce, #31430 or #31460) in 2.5% non-fat dried milk/TBS-T for 1 hour at RT. HRP-conjugated proteins were visualized with Super Signal West-Pico Chemiluminescent Substrate (ThermoFisher Scientific, #34087), followed by membrane autoradiography

Statistical analysis

Statistical analyses were performed using GraphPad Prism 9.3 software. Values were expressed as mean ± standard error of the mean (SEM). Differences were considered significant when $p < 0.05$ (*$p < 0.05$, **$p < 0.01$, ***$p < 0.001$). Data distribution was analysed in all cases, and non-parametric tests were applied when necessary. In the latter scenario, statistical differences were calculated according to Mann–Whitney tests or to Kruskal-Wallis test with Dunn's correction for multiple comparisons. For grouped data, a two-way analysis of variance (ANOVA) was carried out with Sidak´s or Tukey´s post hoc test to account for multiple comparisons. In the case of YAP localization analyses, the ratio between YAP fluorescence intensity in the nucleus versus cytoplasm was calculated. For statistical reasons, a log transformation was applied to the data since the relative likelihood of

sampling from a Gaussian versus a lognormal distribution was computed and the lognormal distribution was more likely.

Results

p73 is required for endothelial junction assembly during angiogenic sprouting and orchestrates transcriptional programs involved in cell-cell adhesion and blood vessel morphogenesis

To investigate the underlying mechanism by which p73 arranges the formation of vascular sprouts, we used a well-established angiogenesis model from iPSCs. Wild type (WT)- and p73KO-iPSCs were differentiated to generate IB4 positive (IB4+) sprouts (Figure 1A). Endothelial cells in WT-sprouts established a front-rear polarity at the leading edge, where tip-cells adopted a finger-like shape with slightly low levels of VE-Cadherin that appears mainly cytoplasmic (Figure 1A and B, yellow arrows). These cells directed migration at the leading pole through the formation of thin filopodia (Figure 1B, yellow dashed arrows) and stress fiber formation (yellow arrowheads). Tip-cells polarized rear-ends were associated to stalk-cells via sharp and linear adherens junctions (AJ) (Figure 1A, white arrow). However, p73KO-sprouts lack front-rear polarity. The few IB4+sprouts that were detected had completely altered junctional morphologies, independently of the cell position, with VE-Cadherin and β-catenin scattered through the cell cytoplasm (Figure 1A, red arrows) and an increase in actin bundles forming stress fibers (Figure 1B, red arrows). Thus, p73-deficiency not only affected the polarization of the sprouts, but also their cytoskeleton. Indeed, while WT stalk-cells (Figure 1B, blue dashed box) established AJ with a linear VE-Cadherin pattern that strongly interacted with F-actin (white arrows) and displayed junction-associated branched actin filaments (white arrowheads), p73KO-sprouts cells had little or no branched actin at cell junctions (red arrowheads).

In order to elucidate the molecular basis of p73 regulation of intercellular junctions, we compared the transcriptomes of p73KO-iPSCs transfected with an empty vector (*Trp73-/-* cells) with those after TAp73 re-expression (+TAp73). The DESeq2 analysis identified 301 DEGs with a p-adj<0.05 (Supplementary Table 1). Functional annotation clustering of the 235 upregulated genes revealed the implication of these DEGs in biological processes (BPs) such as development, cell motility, blood vessel morphogenesis, cell-cell adhesion and actin organization, among others (Figure 1C, left graph and Supplementary Table 2). In particular, some of the GO terms with the higher fold enrichment were related to cell junction organization (GO:0034330, Fold enrichment= 5.97, FDR 1×10^{-3}), while the BPs with the highest significance corresponded to tissue development (GO:0009888, Fold enrichment=3.28, FDR 1.77×10^{-17}) (Supplementary Table 2). Analysis from the clusters "cell-cell adhesion" and "blood vessel morphogenesis" to generate an enrichment map (Figure 1C, right graph) showed that almost half of the DEGs (47%) in the "cell-cell adhesion" cluster were common to all the GO terms strongly associated to this cluster (FDR ranging from 1.65×10^{-12} to 3.09×10^{-7}). Similarly, the BPs included in the "blood vessel morphogenesis" cluster shared one third of the DEGs (FDR ranging from 5.23×10^{-9} to 8.08×10^{-3}), altogether suggesting that there is a preserved gene set which is central to the establishment of cell-junctions and the formation of blood vessels that is regulated by TAp73, all consistent with the reported TAp73 involvement in epithelial architecture [38].

To support TAp73 requirement for proper EC assembly and sprout formation, we applied the same approach to mESCs with specific inactivation of the TAp73 isoform (E14-TAp73KO, [22]. Again, lack of TAp73 strongly impaired the formation of sprouts when compared to WT, but the effect was less dramatic than in p73KO-EBs and

some ERG+ sprouts were found (Figure 1D). In WT-sprouts, EC established sharp AJ with linear VE-Cadherin/β-catenin colocalized staining (Figure 1D, white arrows). However, no proper AJ were observed in TAp73KO sprouts, and VE-Cadherin staining was attenuated and appeared as dots scattered through the cytoplasm. Few EC, mostly located at the base of the sprout, displayed intercellular β-catenin staining (red arrows), but the majority showed thick intercellular accumulation of β-catenin (red arrowhead). These data corroborate that TAp73 isoform is necessary for the establishment of EC junctions during sprouting angiogenesis.

To further reinforce our observations, we revisited a published RNA-seq study in mESCs, comparing parental E14TG2α cells to E14-TAp73KO, either under proliferation conditions (Day 0, D0) or after three days of EB-induced differentiation (D3), when TAp73 is known to be upregulated [22]. In line with our previous results, clustering analysis of downregulated DEGs (Figure 1D, bottom graph) disclosed BPs significantly associated (FDR<0.05) with development, cell communication, cell-cell adhesion and blood vessels morphogenesis. Interestingly, the molecular interaction networks (Figure 1D, right panel) confirmed that, concomitantly with the reported TAp73 upregulation from D0 to D3, the number of shared genes within the GO terms of the clusters, the fold enrichment and, particularly, the FDR increased at D3, altogether strengthening the idea of p73 as a regulator of the vascular architecture through the control of transcriptional programs involved in cell junction establishment.

TAp73 regulates Angiomotin expression and downstream function

To identify possible p73-effector targets, we performed a comparative analysis using: i) the DEGs from the above-RNA-seq mentioned experiments in iPSCs and mESCs; ii) published transcriptomic data of upregulated DEGs after TAp73 expression in p73KO mouse epithelial granulosa cells [39]; and iii) a list of p73 putative targets identified by ChIP-seq [40]. Some of the overlapping genes between these studies (Figure 2A) were well-known p73-transcriptional targets, such as the *Mdm2* [41, 42], *Cdkn1a* [43], *Itgb4* [44], or *Trim32* [45], backing up the validity of this model to identify TAp73 target genes. Interestingly, among the overlapping genes, we found the angiomotin family members *Amotl1,* with predicted p73 binding sites [39] and *Amot,* not yet described as a p73 target. AMOT contributes to the assembly and stability of EC junctions [5], controls polarization of vascular tip-cells [7, 46] and integrates spatial cues from the extracellular matrix to establish functional vascular networks [47], altogether making AMOT an interesting candidate as a p73-downstream effector in the maintenance of EC junctional integrity.

Expression analysis of WT-E14 mESCs during differentiation corroborated that, coinciding with an increase in TAp73 levels from D0 to D3 (Figure 2B), there was a strong upregulation of Amot expression at RNA and protein levels (Figure 2C and D, respectively, blue bars) and, to a much lesser extent, of Amotl1. This enhancement of Amot expression, but not of Amotl1, was significantly hindered in the absence of TAp73 (Figure 2C and D, red bars), suggesting that endogenous TAp73 plays a role in angiomotin upregulation during differentiation. Consistently, Amot levels were abated in p73KO-iPSCs (Figure 2E and F) and exogenous expression of TAp73 in these cells induced AMOT (24 hours after maximum TAp73 exogenous expression; then the effect subsided; Supplementary Figure 1A). Moreover, when using a well-known model for inducible TAp73 expression, like the HA-TAp73-Saos2-Tet-On cells, HA-TAp73-induction by doxycycline treatment prompted a significant increase in *AMOT* expression (Supplementary Figure 1B), suggesting that p73 regulation of this gene could occur in different cellular contexts.

To demonstrate that *AMOT* was a direct TAp73-transcriptional target, we searched *in silico* for p73 response elements (RE) within the *AMOT* proximal promoter and regulatory region and identified a strong p73RE (score:

13.3) located in intron 1. ChIP assays were carried-out in HA-TAp73-Saos2-Tet-On cells (Figure 2G). Crosslinked cellular extracts were immunoprecipitated (IP) using either an anti-TAp73 to detect all TAp73, or anti-HA antibodies for the induced HA-TAp73 (Figure 2G). As negative controls, we IP with an isotype immunoglobulin (IgG) or an anti-p53 antibody. Both anti-HA and anti-TAp73 pulldowns showed a significant enrichment compared to negative controls (Figure 2G), demonstrating that *AMOT* is a direct TAp73 transcriptional target.

In an attempt to move towards an EC model, we differentiated iPSC into IB4+EC and asked whether previously reported angiomotin expression during differentiation [48, 49] was p73-mediated (Supplementary Figure 1C, D). Comparison between AMOT levels in WT-EBs (P0) and IB4+EC in their first passage (P1) corroborated that, as reported, AMOT-p130 expression increased with differentiation, and even though the levels decreased with successive passages (P1 vs P3), they were always lower in p73-deficient EC, independently of passage number (Supplementary Figure 1D).

We further investigated the need of p73 function for AMOT proper expression using the HUVEC endothelial cell model. TAp73 levels are low in HUVEC; nevertheless, silencing of *TP73* gene with short hairpin RNA (+shp73, p73KD) was robust (Figure 2H) compared to the non-infected control (CTR) and the empty vector-transduced cells (VECTOR). p73KD significantly affected AMOT expression at RNA and protein levels (Figure 2H, I, I') and also altered its localization. Orthogonal projections of confocal images demonstrated that in CTR and VECTOR cells, AMOT was detected at the intercellular junctions, together with VE-Cadherin (Figure 2I, white arrow and orthogonal projection), but this localization was largely lost in +shp73 cells (dashed white arrow, and orthogonal projection side quantification). AMOT levels and pattern expression could be reinstated by treatment of +shp73 HUVEC with XAV939, a tankyrase inhibitor that is known to efficiently stabilize AMOT [50] (Figure 2I, I').

Next, we addressed whether p73 regulation of *AMOT* impinged on its downstream functions. Even though it is not yet clear how AMOT acts to promote angiogenesis *in vivo* [47], one of its reported scaffolding functions is the cytoplasmic sequestration of YAP [51]. YAP promotes barrier function maintenance [52] and gets relocated to the nucleus upon disruption of cell junctions [53]. Thus, we used YAP nuclear/cytoplasmic ratio as a readout of AMOT function. Confocal microscopy analysis in non-treated control cultures showed EC with frequent YAP nuclear exclusion (Figure 3A, yellow arrowheads) and similar nuclear/cytoplasmic ratios between CTR and VECTOR cells (right graph). Downregulation of p73 biased YAP distribution toward the nucleus (Figure 3A, yellow arrows) as reflected by a significantly higher YAP nuclear/cytoplasmic ratio, indicating that lack of p73 altered YAP localization in EC. Treatment of +shp73 cells with XAV939 recovered AMOT junctional localization (Figure 3A, white arrows) and correlated with an increase in YAP nuclear exclusion (dashed yellow arrows) and a significant decrease of the nuclear/cytoplasmic ratios to those similar to controls (right graph), demonstrating that the attenuated AMOT levels were accountable for the observed changes.

AMOT mediates contact inhibition by directly binding and sequestering YAP at the plasma membrane [51]. Thus, we sought to address if p73-downregulation would affect YAP cytoplasmic sequestration triggered by cell-cell contact. In sparse cultures, YAP protein was predominantly localized in the nucleus in controls and +shp73 HUVEC (Figure 3B and C, yellow arrows), with cells showing YAP nuclear/cytoplasmic ratios over 1.68 (Figure 3B, right graph) which correlated with a high percentage of proliferating cells (Figure 3C, right graph). As expected, in confluent control cultures many cells displayed YAP nuclear exclusion (Figure 3B and C, white arrows) and lower YAP nuclear/cytoplasmic ratio, all associated with a strong decrease in proliferating cells

(Figure 3C). Conversely, in +shp73 EC under the same confluency conditions, we detected little nuclear exclusion (yellow arrows) and the nuclear/cytoplasmic ratio barely changed between the two seeding conditions (low [1.57 mean ratio] vs. high-density [1.46 mean ratio]). Moreover, AMOT/YAP-dependent contact-inhibition of cell proliferation was abated in the absence of p73 (Figure 3C). These observations place p73 as a novel regulator of the AMOT/YAP contact-inhibition pathway, essential for the fine tuning between junctional stability and angiogenic activation of ECs.

p73 regulates endothelial junction dynamics via AMOT

Next, we asked whether TAp73 controls the establishment of EC junctions, at least in part, through the regulation of AMOT. Confirming our previous observations, confocal microscopy analysis of +shp73 HUVEC confluent cultures revealed a strong alteration of AJ, visualized by VE-Cadherin staining (Figure 3B and 5A). To accurately describe those differences, we took advantage of previous studies that correlated AJ morphology with cellular activities [54]. We observed that CTR and VECTOR cells frequently showed thick/reticular and reticular VE-Cadherin staining at the cell junctions (Figure 4A, pink and green arrow, respectively). They also establish straight and thick junctions (purple and orange arrows) that resemble the stalk-cell behavior [54]. However, interrupted serrated junctions (yellow arrows, VE-Cadherin fingers herein) were present in lesser proportion in controls. Strikingly, p73KD modified the distribution of junctional categories resulting in a sharp increase of fingers (Figure 4A, yellow arrows and bars). This type of interrupted junctions has been associated with actively rearranging cells and augmented permeability in confluent monolayers [52, 55, 56]. Furthermore, p73KD caused a highly significant decrease in linear and reticular junctions (pink and green bars), which are required to maintain junction integrity [57]. In line with this, p73KD led to junctional breaks in the monolayer (Figure 4A, white arrows). Analysis of Tight junctions (TJ) by ZO-1 expression revealed an interrupted ZO-1 staining pattern, reflecting the accompanying alteration on TJ upon p73KD (Supplementary Figure 2).

In resting controls EC, cortical actin bundles associated with linear and reticular VE-cadherin junctions (Figure 4B, white arrows) are known to be critical for the regulation of barrier function [57]. In these monolayers, the discontinuous serrated junctions can be associated with stress fibers [58] that form actin stellate arrangements at cell-cell borders (dashed white arrow). These junctional fibers are increased in response to permeability-enhancing factors, such as TNF [58]. In accordance with the enhanced finger-like junctions in p73KD cells, we observed an increase in actin bundles appearing as stress fibers in these cells (Figure 4B, white arrowheads). These observations demonstrate that p73 is involved in the remodeling of endothelial junctions and the associated cytoskeleton and is required for the formation of reticular junctions and the repression of VE-Cadherin fingers formation, altogether potentially leading to defects in paracellular permeability.

To demonstrate AMOT requirement for p73 regulation of EC junction dynamics, we attempted to rescue p73KD-junctional defects by stabilizing endogenous AMOT protein. As before, XAV939 treatment of p73KD cells increased AMOT levels, returning AMOT to its colocalization with VE-Cadherin and ZO-1 and reshaping the morphology of AJ and TJ (Figures 5A, yellow arrows and Supplementary 1, respectively). Furthermore, morphometric analysis demonstrated that AMOT stabilization significantly recuperated the formation of reticular junctions and reduced the formation of fingers in the treated p73KD HUVEC monolayers (Figure 5A, lower panel). This restoration of linear and reticular junctions is concomitant with actin reorganization, that now appear as cortical actin bundles like in the controls (Figure 5B). Altogether these data unequivocally demonstrate that the

stabilization of AMOT in p73KD HUVEC restored endothelial junctional dynamics and integrity; therefore, p73 regulates intercellular junction dynamics, at least in part, through the regulation of AMOT.

p73 is required for vascular barrier integrity *in vitro* and *in vivo*

To demonstrate the physiological relevance of p73 regulation of EC junctional dynamics we addressed whether p73-downregulation in EC translated into functional defects. Analysis of transendothelial permeability to dextran molecules revealed a significant increase in permeability in p73KD cells (Figure 6A). In addition, HUVEC monolayer barrier integrity was monitored in real-time by transendothelial electrical resistance (TEER) measurements (Figure 6B) and a significant decrease in TEER was observed in p73KD cultures. TEER results showed that p73KD significantly reduced cell membrane resistance (Rb) values, which inversely correlates to paracellular permeability (Figure 6B). However, did not affect alpha values, which reflect cell–matrix interactions, or in cell membrane capacitance, suggesting that the main effect of p73 downregulation, under the tested cell culture conditions, is the disruption of cell–cell junctions.

Finally, to ask if p73 and its isoforms play a physiological role in the maintenance of barrier integrity *in vivo*, we used mouse retinas to model physiological angiogenesis [59]. In retinal vessels, *Amot* is ubiquitously expressed at post-natal day 7 (P7) and is known to be essential for endothelial tip cell migration [47]. We detected significantly lower levels of *Amot* in the absence of p73 in P7 whole retina extracts by qRT-PCR (Figure 6C). VE-Cadherin staining in whole-mount retinas from WT and p73KO mice revealed profound differences in the arrangement of EC. Whereas in WT-retinas, VE-Cadherin delineates junctions that were thin, and mostly linear and continuous in all IB4+ vessels (Figure 6D, white arrows), in p73KO-retinas the EC junctions were tortuous with interrupted VE-Cadherin staining (yellow arrows). In WT-vessels we detected few unicellular segments lacking VE-Cadherin (Figure 6D, white arrowhead), while in p73KO-retinas there were many IB4-segments lacking VE-Cadherin staining (yellow arrows), even in multicellular vessels of normal caliber (blue arrowheads), indicative of defects in the establishment of multicellular tubes [17]. On the leading front of the retinas, the defective p73KO sprout morphology frequently correlated with aggregations of IB4+EC close to sprouts with very little VE-Cadherin (Figure 6D, blue arrows), arguing that the migration and/or the rearrangement of EC are perturbed in p73-defective vessels, and suggesting that vessels may have failed to anastomose or stabilize connections following sprouting. These defects in vessel morphology were coupled to defects in function, since p73KO and TAp73KO retinas, but not DNp73KO, exhibited large hemorrhages at the angiogenic front and at the vascular network in the remodeling retina plexus (Figure 6E). Altogether, our data strongly demonstrate that p73 plays a predominant role in maintaining the endothelial barrier function and that TAp73 is necessary for the maintenance of junctional integrity *in vivo*, regulating the rearrangements of EC whilst preventing bleeding in developing vessels.

Discussion

The present work contributes to the landscape of p73 function in angiogenesis by presenting a comprehensive study in healthy endothelial cells which express physiological *TP73* levels. Our results provide an understanding of the mechanism by which p73 regulates intercellular junction dynamics in ECs, demonstrating that p73 regulate endothelial junctional dynamics, being essential for the maintenance of the endothelial barrier.

Endothelial junctions play a coordinating role in sprouting angiogenesis by polarizing the activity of the migration machinery and maintaining sprout cohesion [2]. Using 3D-endothelial differentiation models, we show that lack of p73, and TAp73 in particular, results in a strong impairment of the formation of endothelial sprouts and the establishment of AJ, demonstrating TAp73 requirement for these processes. Our *in vivo* data also support this

scenario, since DNp73 was dispensable for the integrity of endothelial junctions in mice retinal vasculature, while lack of TAp73 led to functional defects. Nevertheless, specific elimination of TAp73 caused less dramatic defects than the total elimination of *TP73*, confirming the requirement of DNp73 pro-angiogenic function for a complete vascular morphogenesis process [9].

Even though TAp73 and DNp73 could have proangiogenic functions, it has been proposed that there may be differences in the mechanism by which they exert their activation and promotion of angiogenesis [60]. In agreement with the proposed function of p73 as a tissular architect [38] and supporting our hypothesis that p73 exerts a role on sprouting angiogenesis through the regulation of cell junctions, GO analysis of p73KO-iPSCs +TAp73 revealed that TAp73 orchestrates transcriptional programs involved in the regulation of cell-cell adhesion, developmental morphogenesis, and blood vessel morphogenesis. Similar results were obtained when revisiting an RNA-seq study in mESCs, comparing parental E14TG2α cells to E14-TAp73KO cells [22]. A comparative analysis between several published transcriptomic data and a list of p73 putative targets identified by ChIP-seq led us to focus our interest on AMOT, a member of the angiomotin family which is required for proper TJ and AJ activity [7], therefore contributing to preserve the sprout cohesion [4, 6, 7] and vascular permeability [5]. We identified *AMOT* as a direct TAp73 transcriptional target and showed that p73KD not only impinged in *Amot* expression, but also hindered its downstream functions, like the capacity to sequester YAP at intercellular junctions. Finally, the stabilization of endogenous of AMOT levels in p73KD EC treated with a tankyrase inhibitor [50] restored the junctional defects caused by p73-deficiency, altogether conclusively demonstrating that p73 regulates intercellular junction dynamics, at least in part, through the regulation of AMOT.

However, it is important to keep in mind that YAP and p73 functional interaction is complex. YAP interacts with p73 and behaves as its coactivator of pro-apoptotic genes [61]; in turn, p73 expression is essential for the recruitment of YAP to PML-nuclear bodies following DNA damage [61, 62], altogether suggesting that impaired p73 function could affect YAP activity at many levels in an AMOT-dependent and independent way. Thus, a deeper analysis would be required to fully untangle YAP/p73 functional interaction.

Knockdown of p73 in HUVEC directly impaired junctional and actin dynamics, affecting the establishment of both AJ and TJ, in particular reducing reticular junction formation. The idea of an interactive regulation between VE-Cadherin-mediated cell adhesion and actin dynamics in the control of barrier function has been previously introduced [57]. Thus, reduction of reticular junctions affects VE-Cadherin remodeling [63] and has been linked to increased permeability in cultured EC [64]. Accordingly, p73 requirement for the establishment of VE-Cadherin reticular junctions could intertwine with TAp73 modulation of transcriptional programs regulating actin cytoskeleton dynamics [25] and would impact on endothelium integrity. Our observations not only reveal that p73 function is required for the formation of reticular junctions, but also to regulate the emergence of fingers, linking p73 function to the maintenance of the vascular barrier. Indeed, lack of p73 has functional consequences *in vitro* and *in vivo*, like enhanced permeability and hemorrhages, respectively. Therefore, p73 seems to play a predominant role in maintaining the integrity of the endothelial barrier in the absence of any stimuli. Endothelial barrier integrity is fundamental to ensure vascular and tissue homeostasis; consequently, in many diseases, the vascular barrier disintegrates, and leakage may become chronic. In cancer, blood vessels undergo changes fostered by the abnormal tumor microenvironment, including defective endothelial junctions that leads to increased permeability and leakage [65]. Based in our data it is feasible to speculate that p73 deregulation might play a role

in the chronic vascular hyperpermeability associated with tumor angiogenesis [66] which represents a key point for future studies.

We propose a new model in which TAp73 acts as a vascular architect integrating transcriptional programs that will impinge with AMOT/YAP signaling to maintain junctional dynamics and integrity, whilst balancing endothelial cell rearrangements in angiogenic vessels. This situates p73 function in the hub of upstream regulators that control how endothelial cells establish and maintain adequate junctions to shape functional vascular networks, with important consequences in the maintenance of vascular homeostasis.

References

[1] L. Claesson-Welsh, E. Dejana and D. M. McDonald Permeability of the Endothelial Barrier: Identifying and Reconciling Controversies **Trends in Molecular Medicine** *27* (2021) 314-331. DOI: https://doi.org/10.1016/j.molmed.2020.11.006.

[2] A. Szymborska and H. Gerhardt Hold Me, but Not Too Tight—Endothelial Cell–Cell Junctions in Angiogenesis **Cold Spring Harbor Perspectives in Biology** *10* (2018).

[3] Y. A. Komarova, K. Kruse, D. Mehta and A. B. Malik Protein Interactions at Endothelial Junctions and Signaling Mechanisms Regulating Endothelial Permeability **Circulation research** *120* (2017) 179-206. DOI: 10.1161/CIRCRESAHA.116.306534.

[4] K. Aase, M. Ernkvist, L. Ebarasi, L. Jakobsson, A. Majumdar, C. Yi, O. Birot, Y. Ming, A. Kvanta, D. Edholm, P. Aspenström, J. Kissil, L. Claesson-Welsh, A. Shimono and L. Holmgren Angiomotin regulates endothelial cell migration during embryonic angiogenesis **Genes Dev** *21* (2007) 2055-2068. DOI: 10.1101/gad.432007.

[5] A. Bratt, O. Birot, I. Sinha, N. Veitonmäki, K. Aase, M. Ernkvist and L. Holmgren Angiomotin Regulates Endothelial Cell-Cell Junctions and Cell Motility **Journal of Biological Chemistry** *280* (2005) 34859-34869.

[6] M. Ernkvist, N. L. Persson, S. Audebert, P. Lecine, I. Sinha, M. Liu, M. Schlueter, A. Horowitz, K. Aase, T. Weide, J.-P. Borg, A. Majumdar and L. Holmgren The Amot/Patj/Syx signaling complex spatially controls RhoA GTPase activity in migrating endothelial cells **Blood** *113* (2009) 244-253. DOI: 10.1182/blood-2008-04-153874.

[7] Y. Zheng, S. Vertuani, S. Nyström, S. Audebert, I. Meijer, T. Tegnebratt, J.-P. Borg, P. Uhlén, A. Majumdar and L. Holmgren Angiomotin-Like Protein 1 Controls Endothelial Polarity and Junction Stability During Sprouting Angiogenesis **Circulation Research** *105* (2009) 260-270. DOI: 10.1161/CIRCRESAHA.109.195156.

[8] I. Dulloo, B. H. Phang, R. Othman, S. Y. Tan, A. Vijayaraghavan, L. K. Goh, M. Martin-Lopez, M. M. Marques, C. W. Li, De Y. Wang, Maria C. Marín, W. Xian, F. McKeon and K. Sabapathy Hypoxia-inducible TAp73 supports tumorigenesis by regulating the angiogenic transcriptome **Nature Cell Biology** *17* (2015) 511-523. DOI: 10.1038/ncb3130.

[9] R. Fernandez-Alonso, M. Martin-Lopez, L. Gonzalez-Cano, S. Garcia, F. Castrillo, I. Diez-Prieto, A. Fernandez-Corona, M. E. Lorenzo-Marcos, X. Li, L. Claesson-Welsh, M. M. Marques and M. C. Marin p73 is required for endothelial cell differentiation, migration and the formation of vascular networks regulating VEGF and TGFβ signaling **Cell Death & Differentiation** *22* (2015) 1287-1299. DOI: 10.1038/cdd.2014.214.

[10] M. Stantic, H. A. M. Sakil, H. Zirath, T. Fang, G. Sanz, A. Fernandez-Woodbridge, A. Marin, E. Susanto, T. W. Mak, M. Arsenian Henriksson and M. T. Wilhelm TAp73 suppresses tumor angiogenesis through repression of proangiogenic cytokines and HIF-1α activity **Proceedings of the National Academy of Sciences** *112* (2015) 220. DOI: 10.1073/pnas.1421697112.

[11] P. Vikhreva, G. Melino and I. Amelio p73 Alternative Splicing: Exploring a Biological Role for the C-Terminal Isoforms **Journal of Molecular Biology** *430* (2018) 1829-1838. DOI: https://doi.org/10.1016/j.jmb.2018.04.034.

[12] I. Dulloo, P. B. Hooi and K. Sabapathy Hypoxia-induced DNp73 stabilization regulates Vegf-A expression and tumor angiogenesis similar to TAp73 **Cell Cycle** *14* (2015) 3533-3539. DOI: 10.1080/15384101.2015.1078038.

[13] I. Amelio, S. Inoue, E. K. Markert, A. J. Levine, R. A. Knight, T. W. Mak and G. Melino TAp73 opposes tumor angiogenesis by promoting hypoxia-inducible factor 1α degradation **Proceedings of the National Academy of Sciences** *112* (2015) 226. DOI: 10.1073/pnas.1410609111.

[14] A. Yang, N. Walker, R. Bronson, M. Kaghad, M. Oosterwegel, J. Bonnin, C. Vagner, H. Bonnet, P. Dikkes, A. Sharpe, F. McKeon and D. Caput p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours **Nature** *404* (2000) 99-103. DOI: 10.1038/35003607.

[15] K. Bentley, C. A. Franco, A. Philippides, R. Blanco, M. Dierkes, V. Gebala, F. Stanchi, M. Jones, I. M. Aspalter, G. Cagna, S. Weström, L. Claesson-Welsh, D. Vestweber and H. Gerhardt The role of differential VE-cadherin dynamics in cell rearrangement during angiogenesis **Nature Cell Biology** *16* (2014) 309-321. DOI: 10.1038/ncb2926.

[16] M. Giannotta, M. Trani and E. Dejana VE-Cadherin and Endothelial Adherens Junctions: Active Guardians of Vascular Integrity **Developmental Cell** *26* (2013) 441-454. DOI: 10.1016/j.devcel.2013.08.020.

[17] L. Sauteur, A. Krudewig, L. Herwig, N. Ehrenfeuchter, A. Lenard, M. Affolter and H.-G. Belting Cdh5/VE-cadherin Promotes Endothelial Cell Interface Elongation via Cortical Actin Polymerization during Angiogenic Sprouting **Cell Rep** *9* (2014) 504-513. DOI: 10.1016/j.celrep.2014.09.024.

[18] E. Dejana, F. Orsenigo and M. G. Lampugnani The role of adherens junctions and VE-cadherin in the control of vascular permeability **Journal of Cell Science** *121* (2008) 2115-2122. DOI: 10.1242/jcs.017897.

[19] A. Lenard, E. Ellertsdottir, L. Herwig, A. Krudewig, L. Sauteur, H.-G. Belting and M. Affolter In Vivo Analysis Reveals a Highly Stereotypic Morphogenetic Pathway of Vascular Anastomosis **Developmental Cell** *25* (2013) 492-506. DOI: https://doi.org/10.1016/j.devcel.2013.05.010.

[20] F. Tissir, A. Ravni, Y. Achouri, D. Riethmacher, G. Meyer and A. M. Goffinet DeltaNp73 regulates neuronal survival in vivo **Proceedings of the National Academy of Sciences** *106* (2009) 16871. DOI: 10.1073/pnas.0903191106.

[21] M. Martin-Lopez, L. Maeso-Alonso, S. Fuertes-Alvarez, D. Balboa, V. Rodríguez-Cortez, J. Weltner, I. Diez-Prieto, A. Davis, Y. Wu, T. Otonkoski, E. R. Flores, P. Menéndez, M. M. Marques and M. C. Marin p73 is required for appropriate BMP-induced mesenchymal-to-epithelial transition during somatic cell reprogramming **Cell Death Dis** *8* (2017) e3034-e3034. DOI: 10.1038/cddis.2017.432.

[22] L. López-Ferreras, N. Martínez-García, L. Maeso-Alonso, M. Martín-López, Á. Díez-Matilla, J. Villoch-Fernandez, H. Alonso-Olivares, M. M. Marques and M. C. Marin Deciphering the Nature of Trp73 Isoforms in Mouse Embryonic Stem Cell Models: Generation of Isoform-Specific Deficient Cell Lines Using the CRISPR/Cas9 Gene Editing System **Cancers (Basel)** *13* (2021). DOI: 10.3390/cancers13133182.

[23] J. Au - Davis, S. P. Au - Crampton and C. C. W. Au - Hughes Isolation of Human Umbilical Vein Endothelial Cells (HUVEC) **JoVE** (2007) e183. DOI: doi:10.3791/183.

[24] É. Bálint, A. C. Phillips, S. Kozlov, C. L. Stewart and K. H. Vousden Induction of p57^{KIP2} expression by p73β **Proceedings of the National Academy of Sciences** *99* (2002) 3529. DOI: 10.1073/pnas.062491899.

[25] S. Fuertes-Alvarez, L. Maeso-Alonso, J. Villoch-Fernandez, M. Wildung, M. Martin-Lopez, C. Marshall, A. J. Villena-Cortes, I. Diez-Prieto, J. A. Pietenpol, F. Tissir, M. Lizé, M. M. Marques and M. C. Marin p73 regulates ependymal planar cell polarity by modulating actin and microtubule cytoskeleton **Cell Death Dis** *9* (2018) 1183-1183. DOI: 10.1038/s41419-018-1205-6.

[26] X. Li and L. Claesson-Welsh Embryonic stem cell models in vascular biology **Journal of Thrombosis and Haemostasis** *7* (2009) 53-56. DOI: 10.1111/j.1538-7836.2009.03427.x.

[27] M. S. Irwin, K. Kondo, M. C. Marin, L. S. Cheng, W. C. Hahn and W. G. Kaelin, Jr. Chemosensitivity linked to p73 function **Cancer Cell** *3* (2003) 403-410. DOI: 10.1016/S1535-6108(03)00078-3.

[28] C. Tiruppathi, A. B. Malik, P. J. Del Vecchio, C. R. Keese and I. Giaever Electrical method for detection of endothelial cell shape change in real time: assessment of endothelial barrier function **Proc Natl Acad Sci U S A** *89* (1992) 7919-7923. DOI: 10.1073/pnas.89.17.7919.

[29] B. Marcos-Ramiro, D. García-Weber, S. Barroso, J. Feito, M. C. Ortega, E. Cernuda-Morollón, N. Reglero-Real, L. Fernández-Martín, M. C. Durán, M. A. Alonso, I. Correas, S. Cox, A. J. Ridley and J. Millán RhoB controls endothelial barrier recovery by inhibiting Rac1 trafficking to the cell border **Journal of Cell Biology** *213* (2016) 385-402. DOI: 10.1083/jcb.201504038.

[30] J. Schindelin, I. Arganda-Carreras, E. Frise, V. Kaynig, M. Longair, T. Pietzsch, S. Preibisch, C. Rueden, S. Saalfeld, B. Schmid, J.-Y. Tinevez, D. J. White, V. Hartenstein, K. Eliceiri, P. Tomancak and A. Cardona Fiji: an open-source platform for biological-image analysis **Nature Methods** *9* (2012) 676-682. DOI: 10.1038/nmeth.2019.

[31] S. Anders, P. T. Pyl and W. Huber HTSeq—a Python framework to work with high-throughput sequencing data **Bioinformatics** *31* (2015) 166-169. DOI: 10.1093/bioinformatics/btu638.

[32] S. Anders and W. Huber Differential expression analysis for sequence count data **Genome Biology** *11* (2010) R106. DOI: 10.1186/gb-2010-11-10-r106.

[33] D. W. Huang, B. T. Sherman and R. A. Lempicki Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources **Nature Protocols** *4* (2009) 44-57. DOI: 10.1038/nprot.2008.211.

[34] B. T. Sherman, M. Hao, J. Qiu, X. Jiao, M. W. Baseler, H. C. Lane, T. Imamichi and W. Chang DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update) **Nucleic Acids Research** (2022) gkac194. DOI: 10.1093/nar/gkac194.

[35] P. Shannon, A. Markiel, O. Ozier, N. S. Baliga, J. T. Wang, D. Ramage, N. Amin, B. Schwikowski and T. Ideker Cytoscape: a software environment for integrated models of biomolecular interaction networks **Genome Res** *13* (2003) 2498-2504. DOI: 10.1101/gr.1239303.

[36] T. Hulsen, J. de Vlieg and W. Alkema BioVenn – a web application for the comparison and visualization of biological lists using area-proportional Venn diagrams **BMC Genomics** *9* (2008) 488. DOI: 10.1186/1471-2164-9-488.

[37] A. Mathelier, O. Fornes, D. J. Arenillas, C.-y. Chen, G. Denay, J. Lee, W. Shi, C. Shyr, G. Tan, R. Worsley-Hunt, A. W. Zhang, F. Parcy, B. Lenhard, A. Sandelin and W. W. Wasserman JASPAR 2016: a major expansion and update of the open-access database of transcription factor binding profiles **Nucleic Acids Research** *44* (2016) D110-D115. DOI: 10.1093/nar/gkv1176.

[38] L. Maeso-Alonso, L. López-Ferreras, M. M. Marques and M. C. Marin p73 as a Tissue Architect **Frontiers in Cell and Developmental Biology** *9* (2021).

[39] G. L. Santos Guasch, J. S. Beeler, C. B. Marshall, T. M. Shaver, Q. Sheng, K. N. Johnson, K. L. Boyd, B. J. Venters, R. S. Cook and J. A. Pietenpol p73 Is Required for Ovarian Follicle Development and Regulates a Gene Network Involved in Cell-to-Cell Adhesion **iScience** *8* (2018) 236-249. DOI: 10.1016/j.isci.2018.09.018.

[40] M. Koeppel, S. J. van Heeringen, D. Kramer, L. Smeenk, E. Janssen-Megens, M. Hartmann, H. G. Stunnenberg and M. Lohrum Crosstalk between c-Jun and TAp73α/β contributes to the apoptosis–survival balance **Nucleic Acids Research** *39* (2011) 6069-6085. DOI: 10.1093/nar/gkr028.

[41] X. Q. Wang, W. M. Ongkeko, A. W. S. Lau, K. M. Leung and R. Y. C. Poon A Possible Role of p73 on the Modulation of p53 Level through MDM2 **Cancer Research** *61* (2001) 1598.

[42] X. Zeng, L. Chen, C. A. Jost, R. Maya, D. Keller, X. Wang, W. G. Kaelin, M. Oren, J. Chen and H. Lu MDM2 Suppresses p73 Function without Promoting p73 Degradation **Molecular and Cellular Biology** *19* (1999) 3257. DOI: 10.1128/MCB.19.5.3257.

[43] J. Zhu, J. Jiang, W. Zhou and X. Chen The Potential Tumor Suppressor p73 Differentially Regulates Cellular p53 Target Genes **Cancer Research** *58* (1998) 5061.

[44] N. Xie, P. Vikhreva, M. Annicchiarico-Petruzzelli, I. Amelio, N. Barlev, R. A. Knight and G. Melino Integrin-β4 is a novel transcriptional target of TAp73 **Cell Cycle** *17* (2018) 589-594. DOI: 10.1080/15384101.2017.1403684.

[45] L. Gonzalez-Cano, A. L. Hillje, S. Fuertes-Alvarez, M. M. Marques, A. Blanch, R. W. Ian, M. S. Irwin, J. C. Schwamborn and M. C. Marín Regulatory feedback loop between TP73 and TRIM32 **Cell Death Dis** *4* (2013) e704-e704. DOI: 10.1038/cddis.2013.224.

[46] B. Troyanovsky, T. Levchenko, G. Månsson, O. Matvijenko and L. Holmgren Angiomotin: An Angiostatin Binding Protein That Regulates Endothelial Cell Migration and Tube Formation **Journal of Cell Biology** *152* (2001) 1247-1254. DOI: 10.1083/jcb.152.6.1247.

[47] Y. Zhang, Y. Zhang, S. Kameishi, G. Barutello, Y. Zheng, N. P. Tobin, J. Nicosia, K. Hennig, D. K.-C. Chiu, M. Balland, T. H. Barker, F. Cavallo and L. Holmgren The Amot/integrin protein complex transmits mechanical forces required for vascular expansion **Cell Rep** *36* (2021) 109616. DOI: https://doi.org/10.1016/j.celrep.2021.109616.

[48] S. Pagliari, V. Vinarsky, F. Martino, A. R. Perestrelo, J. Oliver De La Cruz, G. Caluori, J. Vrbsky, P. Mozetic, A. Pompeiano, A. Zancla, S. G. Ranjani, P. Skladal, D. Kytyr, Z. Zdráhal, G. Grassi, M. Sampaolesi, A. Rainer and G. Forte YAP–TEAD1 control of cytoskeleton dynamics and intracellular tension guides human pluripotent stem cell mesoderm specification **Cell Death & Differentiation** *28* (2021) 1193-1207. DOI: 10.1038/s41418-020-00643-5.

[49] Y. Zaltsman, S. Masuko, J. J. Bensen and L. L. Kiessling Angiomotin Regulates YAP Localization during Neural Differentiation of Human Pluripotent Stem Cells **Stem Cell Reports** *12* (2019) 869-877. DOI: 10.1016/j.stemcr.2019.03.009.

[50] W. Wang, N. Li, X. Li, M. K. Tran, X. Han and J. Chen Tankyrase Inhibitors Target YAP by Stabilizing Angiomotin Family Proteins **Cell Rep** *13* (2015) 524-532. DOI: 10.1016/j.celrep.2015.09.014.

[51] B. Zhao, L. Li, Q. Lu, L. H. Wang, C.-Y. Liu, Q. Lei and K.-L. Guan Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein **Genes Dev** *25* (2011) 51-63.

[52] F. Neto, A. Klaus-Bergmann, Y. T. Ong, S. Alt, A.-C. Vion, A. Szymborska, J. R. Carvalho, I. Hollfinger, E. Bartels-Klein, C. A. Franco, M. Potente and H. Gerhardt YAP and TAZ regulate adherens junction dynamics and endothelial cell distribution during vascular development **Elife** *7* (2018) e31037. DOI: 10.7554/eLife.31037.

[53] H.-J. Choi, H. Zhang, H. Park, K.-S. Choi, H.-W. Lee, V. Agrawal, Y.-M. Kim and Y.-G. Kwon Yes-associated protein regulates endothelial cell contact-mediated expression of angiopoietin-2 **Nature Communications** *6* (2015) 6943. DOI: 10.1038/ncomms7943.

[54] J. Cao, M. Ehling, S. März, J. Seebach, K. Tarbashevich, T. Sixta, M. E. Pitulescu, A.-C. Werner, B. Flach, E. Montanez, E. Raz, R. H. Adams and H. Schnittler Polarized actin and VE-cadherin dynamics regulate junctional remodelling and cell migration during sprouting angiogenesis **Nature Communications** *8* (2017) 2210. DOI: 10.1038/s41467-017-02373-8.

[55] A. Hayer, L. Shao, M. Chung, L.-M. Joubert, H. W. Yang, F.-C. Tsai, A. Bisaria, E. Betzig and T. Meyer Engulfed cadherin fingers are polarized junctional structures between collectively migrating endothelial cells **Nature Cell Biology** *18* (2016) 1311-1323. DOI: 10.1038/ncb3438.

[56] M. van der Heijden, G. P. van Nieuw Amerongen, J. van Bezu, M. A. Paul, A. B. J. Groeneveld and V. W. M. van Hinsbergh Opposing effects of the angiopoietins on the thrombin-induced permeability of human pulmonary microvascular endothelial cells **PloS one** *6* (2011) e23448-e23448. DOI: 10.1371/journal.pone.0023448.

[57] A. Abu Taha and H.-J. Schnittler Dynamics between actin and the VE-cadherin/catenin complex **Cell Adhesion & Migration** *8* (2014) 125-135. DOI: 10.4161/cam.28243.

[58] J. Millán, R. J. Cain, N. Reglero-Real, C. Bigarella, B. Marcos-Ramiro, L. Fernández-Martín, I. Correas and A. J. Ridley Adherens junctions connect stress fibres between adjacent endothelial cells **BMC Biology** *8* (2010) 11. DOI: 10.1186/1741-7007-8-11.

[59] A. Uemura, S. Kusuhara, H. Katsuta and S.-I. Nishikawa Angiogenesis in the mouse retina: A model system for experimental manipulation **Experimental Cell Research** *312* (2006) 676-683. DOI: https://doi.org/10.1016/j.yexcr.2005.10.030.

[60] K. Sabapathy p73: a Positive or Negative Regulator of Angiogenesis, or Both? **Molecular and cellular biology** *36* (2015) 848-854. DOI: 10.1128/MCB.00929-15.

[61] F. Conforti, A. E. Sayan, R. Sreekumar and B. S. Sayan Regulation of p73 activity by post-translational modifications **Cell Death Dis** *3* (2012) e285-e285. DOI: 10.1038/cddis.2012.27.

[62] S. Strano, O. Monti, N. Pediconi, A. Baccarini, G. Fontemaggi, E. Lapi, F. Mantovani, A. Damalas, G. Citro, A. Sacchi, G. Del Sal, M. Levrero and G. Blandino The Transcriptional Coactivator Yes-Associated Protein Drives p73 Gene-Target Specificity in Response to DNA Damage **Molecular Cell** *18* (2005) 447-459. DOI: 10.1016/j.molcel.2005.04.008.

[63] J. Cao and H. Schnittler Putting VE-cadherin into JAIL for junction remodeling **Journal of Cell Science** *132* (2019) jcs222893. DOI: 10.1242/jcs.222893.

[64] J. W. Breslin, X. E. Zhang, R. A. Worthylake and F. M. Souza-Smith Involvement of Local Lamellipodia in Endothelial Barrier Function **PLOS ONE** *10* (2015) e0117970. DOI: 10.1371/journal.pone.0117970.

[65] L. Claesson-Welsh Vascular permeability--the essentials **Ups J Med Sci** *120* (2015) 135-143. DOI: 10.3109/03009734.2015.1064501.

[66] J. A. Nagy, A. M. Dvorak and H. F. Dvorak Vascular Hyperpermeability, Angiogenesis, and Stroma Generation **Cold Spring Harbor Perspectives in Medicine** *2* (2012).

[67] F. Grespi and G. Melino P73 and age-related diseases: is there any link with Parkinson Disease? **Aging (Albany NY)** *4* (2012) 923-931. DOI: 10.18632/aging.100515.

[68] R. Tomasini, K. Tsuchihara, M. Wilhelm, M. Fujitani, A. Rufini, C. C. Cheung, F. Khan, A. Itie-Youten, A. Wakeham, M.-S. Tsao, J. L. Iovanna, J. Squire, I. Jurisica, D. Kaplan, G. Melino, A. Jurisicova and T. W. Mak TAp73 knockout shows genomic instability with infertility and tumor suppressor functions **Genes Dev** *22* (2008) 2677-2691. DOI: 10.1101/gad.1695308.

Statement and Declarations

Funding. This work was supported by Grants PID2019-105169RB-I00 (from Spanish Ministerio de Ciencia e Innovación cofinanced by FEDER funds) and LE022P20 (from Junta de Castilla y León) (to M.C.M.). L.M.-A. and J.V.-F. and are funded by Junta de Castilla y León. H.A.-O. and N.M.-G. are supported by a predoctoral scholarship from the Asociación Española contra el Cáncer (AECC).

Competing interests. The authors have no relevant financial or non-financial interests to disclose.

Author Contributions: Conceptualization: L.M.-A., M.M.M. and M.C.M.; investigation: L.M.-A., H.A.-O., N.M.-G., J.V.-F., L.L.-F., L.P.-S., N.C.-A.; methodology: L.M.-A., J.V.-F., L.P.-S., J.M., L. d-P., L.C.-W., M.M.M. and M.C.M.; software: L.M.-A., H.A.-O., L.P.-S., validation: L.M.-A., J.M., L. d-P., M.M.M. and M.C.M.; formal analysis: L.M.-A., L. d-P., M.M.M. and M.C.M.; visualization: L.M.-A., H.A.-O., N.M.-G., M.M.M. and M.C.M.; writing the original draft, review and editing: L.M.-A., H.A.-O., M.M.M. and M.C.M.; general review and editing: All authors; supervision: L.M.-A., M.M.M. and M.C.M.; resources: A.F.-C., M.E.L.-M, B.J., L.H., M.W., J.M., L. d-P., L.C.-W., M.M.M. and M.C.M.; funding acquisition: M.C.M.; project administration: M.M.M. and M.C.M. All authors have read and agreed to the published version of the manuscript

Data availability.

The datasets generated during the current study are available in the OPEN SCAYLE repository https://open.scayle.es/en/dataset/maeso-alonso-et-al-2022

Ethics approval. All animal experiments were carried out in agreement with European and Spanish regulations (Council Directive 2010/63/UE and RD 53/2013, respectively), with the appropriate institutional ethics committee approval (OEBA-ULE-018-2017 and OEBA-ULE-018-2021, Universidad de Leon and Junta de Castilla y Leon).

Table 1. Primary and secondary antibodies used for immunofluorescence.

	Antibody	Host	Dilution	Manufacturer	Catalog Number
Primary	**VE-cadherin**	Goat	1/100	R&D Systems	AF1002
	VE-cadherin (F8)	Mouse	1/500	Santa Cruz Biotechnology	sc9989
	YAP (63.7)	Mouse	1/100	Santa Cruz Biotechnology	101199
	ZO-1 (1A12)	Mouse	1/100	Thermo Fisher	339100
	β-Catenin (14)	Mouse	1/200	BD transduction lab.	61053
	Amot (D2O4H)	Rabbit	1/200	Cell Signalling	43130S
	KI67	Rabbit	1/200	Abcam	ab15580
Secondary	**Alexa Fluor 488** anti Rabbit	Donkey	1/1000	Molecular Probes	A21206
	Alexa Fluor 488 anti Mouse	Goat	1/1000	Molecular Probes	A21131
	Alexa Fluor 546 anti Mouse	Donkey	1/1000	Molecular Probes	A10036
	Alexa Fluor IgG1 594 anti Mouse	Goat	1/1000	Molecular Probes	A21125
	Alexa Fluor 647 anti Mouse	Donkey	1/1000	Molecular Probes	A31571
	Alexa Fluor 647 anti Goat	Donkey	1/1000	Molecular Probes	A21447

Table 2. Primer sequences used for qRT-PCR.

Gene	Specie	Sequence	Reference
18S	Mouse	F 5′-AGTTCCAGCACATTTTGCGAG-3′	[67]
		R 5′-TCATCCTCCGTGAGTTCTCCA-3′	
Amotl1	Mouse	F 5′-ATGTAGCCTCTGGAAGAGTGT-3′	Primer Bank Database ID: 26340072a1
		R 5′-TGAGTGAGGGTTTCCGTGGA-3′	
Amot	Mouse	F 5′-CCGCCAGAATACCCTTTCAAG-3′	Primer Bank Database ID: 23503333a1
		R 5′-CTCATCAGTTGCCCCTCTGT-3′	
TAp73	Mouse	F 5′-GCACCTACTTTGACCTCCCC-3′	[68]
		R 5′-GCACTGCTGAGCAAATTGAAC-3′	
18S	Human	F 5′-GGCGCCCCCTCGATGCTCTTA-3′	Primer Bank Database
		R 5′-GCTCGGGCCTGCTTTGAACAC-3′	
AMOT	Human	F 5′-ACCTCGTGAAGTCATCCTCCCA-3′	Primer Bank Database ID: 63252911c2
		R 5′-CCTCCGAATCTCGCCCTCTA-3′	
TAp73	Human	F 5´-GCACCTACTTCGACCTTCCC-3′	Modified from [68]
		R 5´-GTGCTGCTCAGCAGATTGAAC-3′	

Figure legends

Figure 1. TAp73 is required for the assembly of endothelial junctions during angiogenic sprouting *in vitro* and modulates transcriptional programs involved in cell-cell adhesion and blood vessel morphogenesis. (A, B, D) Immunofluorescence analysis of endothelial adherens junctions in IB4+ (A-B) or ERG+ (D) vascular sprouts. WT and p73KO-iPSC (A-B) or E14-WT- and TAp73KO-ESCs (D) were differentiated via EB formation and 3D culture conditions. After 12 (A, B) or 21 days (D), sprouts were stained for VE-Cadherin (VE-CADH) (blue) (A, B, D), F-ACTIN (green) (B), and β-CATENIN (green) (A, D). Nuclei were counterstained with DAPI (yellow). Scale bar: 20 µm. Magnifications of the areas marked with yellow or blue dashed squares are shown. **(A)** Yellow arrows indicate WT tip-cells, and white arrows point to stalk cells where VE-CADH staining is tightly co-localized with β-CATENIN. p73-deficiency results in altered junctional morphology independently of the cell position (red arrows). **(B)** In WT sprouts, tip-cells show thin filopodia (yellow dashed arrows) and stress fibers (yellow arrowheads), whereas in stalk cells (blue dashed square) VE-cadherin interacts with F-ACTIN (white arrows) and AJs displayed junction-associated branched actin filaments (white arrowheads). Lack of p73 leads to an increase in stress fibers (red arrows) and a decrease of branched actin (red arrowheads) at junctions. **(D,** left panel**)** In WT-cells, EGR+ sprouts establish sharp AJ (white arrows). In the absence of TAp73, only some EGR+ cells establish AJ (red arrows), but the rest have thick intercellular accumulations of β-CATENIN and no proper VE-CADH staining (red arrowhead). Confocal microscopy images are representative of at least three independent experiments. **(C, D)** Functional annotation clustering of up-regulated DEGs (p-adj<0.05) in p73KO-iPSCs after TAp73 re-expression (C, left graph) and downregulated DEGs (p-adj<0.05) in E14-TAp73KO cells under differentiation conditions-Day 3 (D, bottom graph). The number of terms (f) that compose each cluster is indicated. (C, D right panel) Network analysis of Cell-cell adhesion and Blood vessels morphogenesis clusters from iPSCs-RNA-seq (C) and E14-RNA-seq (D, Day 0 top panel, Day 3 bottom panel). Nodes in the graph represent the GO terms included in each annotation cluster. The node color indicates the false discovery rate (FDR) for the DEG association to each term, while the node size represents the Fold Enrichment. The edges connect overlapping terms, with the edge thickness depicting the magnitude of the overlap.

Figure 2. AMOT, a member of the Angiomotin family, is a direct TAp73 transcriptional target. (A) Comparison of the RNA-seq experiments in Figure 1 (upregulated DEGs in p73KO-iPSCs + TAp73 and downregulated DEGs in the case of E14-TAp73KO Day 3) with previously published transcriptomic data and ChIP-seq data from the indicated studies. **(B, C)** qRT-PCR analysis of TAp73 (B), or *Amot* and *Amotl1* expression (C) in mESCs of the indicated genotypes under differentiation conditions. Values correspond to the fold increase relative to E14-WT Day 0 (B) or to their respective D0 values for each genotype (C). At least three independent experiments were performed. 18S Ribosomal RNA was used as housekeeping gene. **(D)** Western blot analysis and quantification of AMOT and AMOTL1 expression in mESCs of the indicated genotypes. Graphs shows the mean of two independent experiments yielding similar results. **(E, F)** qRT-PCR analysis (E) and western blot (F) to evaluate *Amot* expression in WT- and p73KO-iPSCs were performed as before. **(G)** ChIP analysis shows direct binding of TAp73 and HA-TAp73 to the selected p73RE in HA-TAp73β-Saos-2-Tet-On cells following TAp73 induction by Doxycycline treatment (–/+DOXO). ChIP was performed using an isotype-control antibody (rabbit IgG) and anti-p53 as negative controls, or an anti-HA or anti-TAp73 antibodies for quantifying TAp73 binding. qPCR with primers specific to the p73-RE identified in the human *AMOT* promoter was performed and the fold enrichment relative to IgG precipitation is represented. **(H, I, I')** p73 knockdown correlates with lower AMOT

RNA and protein levels (H, I', respectively) and a defective AMOT localization (I) in HUVEC. **(H)** qRT-PCR analysis of TAp73 and *AMOT* expression after p73KD with an shRNA targeting p73 (+shp73). Non-infected HUVEC (CTR) and cells transduced with a non-silencing empty vector (VECTOR) were used as controls. **(I)** Representative confocal micrographs of confluent monolayers from control cells and p73KD cells, with or without treatment with the tankyrase inhibitor XAV939. Cells were immunostained for AMOT (green) and VE-CADH (orange); nuclei were counterstained with DAPI (light blue). Magnifications of the areas marked with white dashed squares are displayed. Orthogonal projections of the magnified areas show AMOT localization at cell junctions colocalizing with VE-CADH. The histograms at the right represent the mean fluorescence intensity (MFI) profiles of AMOT and VE-CADH expression along the red bracket indicated at the orthogonal projection. Scale bar: 20 μm. **(I')** Quantification of AMOT mean fluorescence intensity at cell periphery is shown. At least 100 cells from 3 independent experiments were quantified per condition. In all panels, values represent mean ± SEM of three independent experiments. *p<0.05, **p<0.01, ***p<0.001, ns: non-significant.

Figure 3. p73 regulation of AMOT impinges on its downstream functions and controls AMOT-mediated YAP sequestration during cell contact inhibition. (A) Non-infected control HUVEC (CTR), and cells transduced with a non-silencing empty vector (VECTOR) or with an shRNA targeting p73 (+shp73) were seeded at $7{,}5 \times 10^4$ cells/cm^2 and after 48-72 h, cells were treated with XAV939 for 24 h. Non-treated control cultures display frequent nuclear exclusion (yellow arrowheads) of YAP staining (orange), whereas +shp73 cultures show a biased YAP distribution toward the nucleus (yellow arrows). Immunofluorescence analysis demonstrate that XAV939 treatment restores AMOT (pink) levels and localization at intercellular junctions (white arrows) and correlated with a change in YAP localization in p73KD cells upon treatment (dashed yellow arrows). (**A**, right graph) Quantification of YAP nuclei/cytoplasm ratio after p73KD +/- XAV939 treatment. For these analysis, three independent infections were performed and at least five pictures from each experiment were randomly selected and quantified (n>100 analyzed cells across the three independent experiments). The obtained data followed a logarithmic distribution; thus, for the statistical analysis, a log transformation was applied to the data. The computed P value is indicated in the graph. **(B, C)** Analysis of YAP (red) localization and proliferation (**C,** KI67, green) in HUVEC at different seeding density conditions (Low - 1×10^4 cells/cm^2 versus High density - $7{,}5 \times 10^4$ cells/cm^2/High). Cell delimitation was discerned by β-CATENIN (**B**, green) staining. Nuclei were counterstained with DAPI (**B,** light blue). Scale bar: 20 μm. Under sparse culture conditions (low density) YAP localized mainly at the nucleus (yellow arrows), either in controls or p73KD cells. Upon contact inhibition (high density) many CTR and VECTOR cells displayed YAP nuclear exclusion (white arrows); however, p73KD cells (+shp73) showed little or no nuclear exclusion (yellow arrows) upon confluency. Quantification of YAP nuclei/cytoplasm ratio was performed as in (A) (n>60 cells for Low-density and n>100 for High-density condition). **(C)** Quantification of the proliferation percentage after p73KD (right panel). Bars represent mean ± SEM of three independent experiments. ***p<0.001, ns: no significant.

Figure 4. p73 regulates adherens junction and actin organization *in vitro*. (A, B) Representative confocal microscopy images of confluent HUVEC monolayers showing the alterations of adherens junctional morphologies after p73KD. Non-infected control HUVEC (CTR), and cells transduced with a non-silencing empty vector (VECTOR) or with an shRNA targeting p73 (+shp73) were stained for VE-CADHERIN **(A, B,** green) or F-ACTIN **(B,** red**)**. Nuclei were counterstained with DAPI (light blue). Scale bar: 20 μm. **(A)** Morphological analysis of VE-CADH labelled cell junctions in HUVECs after p73KD. Cell junction morphology analysis was performed based

on previous publications [52]. Briefly, five morphological categories were defined: straight junctions (purple arrow), thick junctions (orange arrow), thick to reticular junctions (pink arrow), reticular junctions (green arrow) and fingers (yellow arrows). White arrows point to cellular gaps. Each image was divided in 36 patches and a morphological category was manually assigned to each patch. Representative patches (right panel) used for morphological classification are shown. Bottom images correspond to the magnifications of areas marked with white dashed squares. Bars represent the mean percentage ± SEM for each type of morphology Three independent transductions experiments were performed and ten pictures per experiment were randomly selected and classified (*n*=30 pictures per condition). p values indicate the statistical differences between +shp73 and VECTOR values (***p<0.001). There were no significant differences between CTR and VECTOR. **(B)** In control cells, cortical actin bundles (labelled in red) associate to VE-Cadherin (green) in linear and reticular junctions (white arrows), whereas the discontinuous junctions form stellate arrangements at cell borders (dashed white arrows). p73KD results in an increase of actin bundles appearing as stress fibers (white arrowheads).

Figure 5. AMOT is a p73-downstream effector for the regulation of endothelial junctions and actin dynamics. (A, B) Confocal microscopy analysis of HUVEC after p73 knockdown and XAV939 treatment. Stabilization of endogenous AMOT levels (**A**, pink) by XAV939 treatment rescues the morphology of endothelial AJ as shown by VE-CADH staining (**A**, orange, yellow arrows; **B,** green) and the organization of F-ACTIN (**B**, red). Nuclei were counterstained with DAPI (blue). Scale bar: 20 µm. **(A,** low panel**)** Quantitative analysis of VE-cadherin cell junction morphology. Bars represent mean ± SEM (n=30 pictures per condition across three independent experiments). p values indicate the statistical differences between +shp73 and VECTOR values (***p<0.001) and between +shp73 untreated and XAV939-treated cells (###p<0.001). There were no significant differences among the morphological types between CTR and VECTOR.

Figure 6. p73 is necessary for endothelial barrier integrity *in vitro* and *in vivo*. (**A**) Permeability assays to 250 kDa fluorescent dextran molecules in HUVEC monolayers comparing non-interfered (CTR), scrambled control (SCR) and p73-knockdown cells by siRNA (sip73). Cells were nucleofected and subsequently plated on the insert well. After 96 h, each insert was transferred to a fresh well plate and FITC-Dextran was added and incubated for 20 min at RT. Fluorescence (485 nm excitation/535 nm emission) was quantified in a plate reader. TAp73 expression level was analyzed by qRT-PCR in each case (left graph). (**B**) ECIS analysis of the effect of p73KD (+shp73) by TEER (Trans-endothelial electric resistance). ECIS mathematical modelling of the TEER analysis yields three values: basolateral membrane resistance values (Rb, left), Alpha values (center) and Cell membrane capacitance (right). Three independent experiments were performed. (**C**) *Amot* mRNA expression levels in WT and p73KO mice retina analyzed by qRT-PCR. **(D, E)** Immunofluorescence analysis of P7 WT, p73KO, TAp73KO **(E)** and DNp73KO **(E)** mice whole mount retinas stained with IB4 (red), anti-VE-CADHERIN (green) **(D)** and anti-TER119 (green) **(E)**. **(D)** Representative confocal microscopy images of vascular networks and the leading edge show linear intercellular junctions (white arrows) with unicellular segments lacking VE-CADH (white arrowhead) in WT vascular network retinas. On the contrary, lack of p73 results in retina vessels with interrupted staining (yellow arrows), even in multicellular vessels (blue arrowheads), and in aggregations of IB4+EC (blue dashed arrows) close to sprouts with very little VE-CADH (blue arrows). Retinas from at least 3 mice per genotype were analyzed. Scale bar: 20µm. **(E)** Vessel integrity was assessed by quantifying the percentage of erythrocytes (TER119+cells) inside or outside the IB4+blood vessels (right panel). At least three mice per genotype were considered, and a minimum of 20 pictures were quantified for each genotype. Bars

represent the mean percentage ± SEM. p value was calculated with respect to the WT littermates for each genotype. *p<0.05 **p<0.01, ***p<0.001, ns: no significant.

Supplementary Figure 1. p73 regulates AMOT levels in different cell types. (A) Amot expression in WT and p73KO-iPSCs+TAp73 correlates with TAp73 expression at RNA **(A,** left graphs**)** and protein **(A,** right panel**)** levels 24 hours after peak TAp73 expression. For transfection experiments, iPSCs were seeded (3.7×10^4 cells/cm^2) on Matrigel™ (Corning, #356231) coated plates and transfected with an empty Vector or a TAp73 expression plasmid using Lipofectamine™ 3000 Transfection Reagent (Invitrogen, # L300008) following the manufacturer´s instructions. Cells were analysed 24 h after transfection. **(B)** TAp73 and *AMOT* expression analysis by qRT-PCR in HA-TAp73β-Saos2-Tet-On following Doxycycline treatment (–/+DOXO), which induces TAp73 expression. Bars in (A) and (B) represent the mean ± SEM of three independent experiments. *p<0.05, ***p<0.001 ns: no significant. **(C)** Schematic drawing of the 2D-endothelial differentiation assay and representative phase-contrast and fluorescence microscopy images. EBs of the studied genotypes were disaggregated and plated (5×10^4 cells/cm^2) in EB medium (DMEM/GlutaMAX™-Gibco, #61965026, 25 mM HEPES, 1.2 mM sodium pyruvate, 19 mM monothioglycerol, 15% FBS) supplemented with 50 ng/ml VEGF-A (Peprotech, #450-32), on 0.1% gelatine-coated plates (non-endothelial, Passage 0). After 72-96h hours with VEGF-A and upon reaching 90% confluency, cultures were trypsinised and replated on 0.1% gelatine-coated plates (endothelial differentiated cells, Passage 1). This step was repeated twice (Passage 2, 3). The cells were stained with biotinylated IB4 (2 µg/ml) to demonstrate their endothelial nature. Scale bar: 50 and 25 µm, respectively. **(D)** AMOT expression was analyzed by western blot in WT and p73KO undifferentiated cells (EBs) and at various passages after differentiation (P1-P3).

Supplementary Figure 2. AMOT is a p73-downstream effector for the regulation of tight junctions. Stabilization of endogenous AMOT levels by XAV939 treatment restores the tight junctions defects induced by the p73KD. AMOT (pink) restoration rescues the morphology of TJs as shown by ZO-1 (orange) staining. Nuclei were counterstained with DAPI (blue). Scale bar: 20 µm.



Maeso-Alonso et al. Figure 1



Maeso-Alonso et al. Figure 2



Maeso-Alonso et al. Figure 3



Maeso-Alonso et al. Figure 4



Maeso-Alonso et al. Figure 5



Maeso-Alonso et al. Figure 6









Maeso-Alonso et al. Supp Figure 1


A
Non treated
XAV939 5μM
CTR
VECTOR
+ shp73
ZO-1 DAPI
AMOT DAPI
ZO-1
AMOT DAPI